"Interchangeable" Biosimilars Get Same Medicare Code As Innovators In Bill
This article was originally published in The Pink Sheet Daily
Executive Summary
Reference product payments could decline as proposed payment amounts would be a blend average sales price of the two products.You may also be interested in...
Biosimilars Would Have Medicare Parity With Innovators Under Reform Bill
The potential for physicians to favor innovator biologics over follow-on biologics because of a reimbursement advantage would be eliminated under an amendment to health care reform legislation adopted by the Senate Finance Committee Sept. 23
Follow-On Biologics: Defeat For Waxman, Win For Health Reform
Rep. Henry Waxman, D-Calif., can perhaps take some comfort in the fact that his defeat on follow-on biologics means his broader health reform legislation may have a greater chance of passage
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports
New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests: